SMART TRIAL Small Annuli Randomized to Evolut or Sapien Study

What is the Purpose of this Study?

This study focuses on individuals who have been recommended for aortic valve replacement for aortic stenosis (disease of the aortic valve). The purpose of the study is to collect and compare the safety and performance of self-expanding (SE) versus balloon expandable (BE) transcatheter aortic valve replacement (TAVR) in patients with small aortic valve. Aortic stenosis occurs if the valve becomes too narrow, causing less blood to flow through and the heart to work harder to pump the same amount of blood with each beat.

A procedure to replace the diseased aortic valve is the standard treatment for aortic stenosis. This can be done by open heart surgery (also called surgical aortic valve replacement), or TAVR, which does not require open heart surgery. Participants in this study will have TAVR. In a TAVR procedure, the transcatheter aortic valve replacement device is inserted through a flexible tube (catheter), which is inserted through an incision in the groin and threaded through the blood vessel. Participants will receive either self-expanding (Evolut) or balloon-expandable (Sapien) devices in order to replace the aortic valve. Researchers will compare the valves to learn which works better in these patients.


Eligibility

  • * Heart Team agrees that the subject is deemed symptomatic and is a candidate for transcatheter aortic valve replacement (TAVR)
  • * Subject has a predicted risk of operative mortality \< 15% as determined by the local Heart Team
  • * Subject has severe aortic stenosis as determined by transthoracic echocardiography (TTE) at rest
  • * Subject has a small aortic annulus as determined by Multi-detector computed tomography (MDCT)
Show more

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

SMall Annuli Randomized To Evolut? or SAPIEN? Trial -SMART TRIAL

Study Details
Disease Type/Condition

Transcatheter Aortic Valve Replacement (TAVR)

Principal Investigator

Makkar, Rajendra

Age Group

Adult

Phase

IV

IRB Number

STUDY00001509

ClinicalTrials.gov ID

NCT04722250

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Transcatheter Aortic Valve Replacement (TAVR)

Principal Investigator

Makkar, Rajendra

Age Group

Adult

Phase

IV

IRB Number

MDT200023EVR012

ClinicalTrials.gov ID

NCT04722250

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org